

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Daiichi Sankyo Launches New Generic Drugs Through its Daiichi Sankyo Espha Subsidiary

Tokyo, Japan (June 18, 2015) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that on Friday, June 19, its generics subsidiary, Daiichi Sankyo Espha, will launch seven new generic drugs with four new active ingredients.

Overview

1. Product names/therapeutic categories

Product name	Therapeutic category	Original brand name
Naftopidil OD Tablets 25mg "DSEP"	Treatment for urination disorder due to enlargement of prostate	Flivas® OD Tablets 25mg, 50mg, 75mg
Naftopidil OD Tablets 50mg "DSEP"		
Naftopidil OD Tablets 75mg "DSEP"		
Metformin Hydrochloride Tablets 250mgMT "DSEP"	Biguanide-type oral hypoglycemic agent	Metgluco® Tablets 250mg, 500mg
Metformin Hydrochloride Tablets 500mgMT "DSEP"		
Letrozole Tablets 2.5mg "DSEP"	Aromatase inhibitor/postmenopausal breast cancer treatment	Femara® Tablets 2.5mg
Oxaliplatin I.V. Infusion Solution 200mg "DSEP" *Additional strength of formula released in 50mg, 100mg in Dec. 2014	Anti-malignant tumor agent	Elplat® I.V. Infusion Solution 200mg

2. Product attributes - Daiichi Sankyo Espha measures

Daiichi Sankyo Espha has continued to maintain a level of quality based on the quality management standards of the Daiichi Sankyo Group. Thanks to initiatives such as the world's first double-sided printing on tablets, Daiichi Sankyo Espha has contributed to innovations in formulation and labeling to make drugs easier to ingest and harder for patients to mistakenly or incorrectly take. These kind of high value-added generic drugs are put forth by Daiichi Sankyo Espha as "premium generics."

Measures to prevent inadvertent ingestion by children

In order to respond to the risk of patient family members, particularly children, taking their medicine by mistake, a new measure has been introduced for Letrozole Tablets (postmenopausal breast cancer treatment).

- C-Guard

This PTP sheet was designed so that tablets can only be extracted if an inner sheet is slid up or down to match up with the position of the tablet, thus helping to prevent children taking the drug by mistake.

(Letrozole Tablets equipped with C-Guard protection)



Innovative design of PTP sheets and tablets

In order to prevent mistaken or inadvertent ingestion, innovations in formulation and labeling are continuing to be developed.

- Easily recognizable original symbols:

PTP sheets feature original symbol marks based on formulation and disease characteristics.

- GS1 data barcode for each tablet:

With the aim of helping to ensure there is no mistaken ingestion of tablets, GS1 data barcodes are printed on the back of PTP sheets.

- Pitch control:

Clear identification of tablets by printing of product names, active ingredients, etc. in fixed positions.

- Double-sided printing (Metformin Hydrochloride Tablets):

Printing of product name and active ingredient content on both sides of tablets to make them easier to distinguish.

- Engraved markings (Naftopidil OD Tablets, Letrozole Tablets):

Code (NFP/LTZ) engraved on tablets to make them easier to distinguish.

Naftopidil OD Tablets 75mg “DSEP”



Metformin Hydrochloride Tablets 250mgMT “DSEP”



Letrozole Tablets 2.5mg “DSEP”



Oxaliplatin I.V. Infusion Solution 200mg “DSEP”



About Daiichi Sankyo Espha

Daiichi Sankyo Espha is a company that manufactures and markets generic drugs, accommodating rising demand based on the spirit of Daiichi Sankyo Group corporate philosophy* of supplying pharmaceuticals to address diverse medical needs. Daiichi Sankyo Espha strives to provide peace of mind for users by fulfilling the most important pharmaceutical criteria of quality, information, and stable supply while delivering the economic benefits of generics.

*Daiichi Sankyo Group corporate philosophy: To contribute to the enrichment of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.

Daiichi Sankyo Espha Company Overview

Company name: Daiichi Sankyo Espha Co., Ltd.

Established: April 1, 2010

Business: Manufacture and sale of pharmaceuticals

Capital: 450 million yen

Representative: Hiroto Yoshikawa, President

Headquarters: 3-5-1, Nihonbashi, Honcho, Chuo-ku, Tokyo